{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:06:41Z","timestamp":1795010801843,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life and are associated with increased susceptibility to opportunistic infections and severe diseases including adult T cell leukemia\/lymphoma and HTLV-1-associated myelopathy-tropical spastic paraparesis. No HTLV-1-specific anti-retrovirals have been developed and it is unclear whether existing anti-retrovirals developed for treatment of human immunodeficiency virus (HIV) have efficacy against HTLV-1. To understand the structural basis for therapeutic binding, homology modelling and machine learning were used to develop a structural model of the HTLV-1 reverse transcriptase. With this, molecular docking experiments using a panel of FDA-approved inhibitors of viral reverse transcriptases to assess their capacity for binding, and in turn, inhibition. Importantly, nucleoside\/nucleotide reverse transcriptase inhibitor but not non-nucleoside reverse transcriptase inhibitors were predicted to bind the HTLV-1 reverse transcriptase, with similar affinity to HIV-1 reverse transcriptase. By strengthening the rationale for clinical testing of therapies such as tenofovir alafenamide, zidovudine, lamivudine, and azvudine for treatment of HTLV-1, this study has demonstrated the power of in silico structural biology approaches in drug design and therapeutic testing.<\/jats:p>","DOI":"10.1186\/s12985-024-02288-z","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T11:02:33Z","timestamp":1704884553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside\/nucleotide reverse transcriptase inhibitors"],"prefix":"10.1186","volume":"21","author":[{"given":"Nicolas","family":"Tardiota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Jaberolansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Lackenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake S.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"6","key":"2288_CR1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79(6):2031\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2288_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1473-3099(19)30402-5","volume":"20","author":"G Schierhout","year":"2020","unstructured":"Schierhout G, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133\u201343.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2288_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/jmv.21738","volume":"82","author":"Y Koga","year":"2010","unstructured":"Koga Y, et al. Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia\/lymphoma in Nagasaki. Japan J Med Virol. 2010;82(4):668\u201374.","journal-title":"Japan J Med Virol"},{"issue":"24","key":"2288_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570\u20137.","journal-title":"Blood"},{"issue":"12","key":"2288_CR5","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1128\/JVI.73.12.10289-10295.1999","volume":"73","author":"GP Taylor","year":"1999","unstructured":"Taylor GP, et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol. 1999;73(12):10289\u201395.","journal-title":"J Virol"},{"issue":"3","key":"2288_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1086\/376531","volume":"188","author":"SA Hill","year":"2003","unstructured":"Hill SA, et al. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis. 2003;188(3):424\u20137.","journal-title":"J Infect Dis"},{"issue":"2","key":"2288_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1172\/JCI113085","volume":"80","author":"S Matsushita","year":"1987","unstructured":"Matsushita S, et al. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest. 1987;80(2):394\u2013400.","journal-title":"J Clin Invest"},{"issue":"5","key":"2288_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/pathogens9050342","volume":"9","author":"F Marino-Merlo","year":"2020","unstructured":"Marino-Merlo F, et al. Antiretroviral therapy in HTLV-1 infection: an updated overview. Pathogens. 2020;9(5):342.","journal-title":"Pathogens"},{"issue":"2","key":"2288_CR9","doi-asserted-by":"publisher","first-page":"e1009271","DOI":"10.1371\/journal.ppat.1009271","volume":"17","author":"M Izaki","year":"2021","unstructured":"Izaki M, et al. In vivo dynamics and adaptation of HTLV-1-infected clones under different clinical conditions. PLoS Pathog. 2021;17(2):e1009271.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2288_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jac\/dkr404","volume":"67","author":"A Trevi\u00f1o","year":"2011","unstructured":"Trevi\u00f1o A, et al. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother. 2011;67(1):218\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"2288_CR11","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell JS, Chappell Keith J. Integrated molecular and immunological features of HTLV-1 infection and disease progression to adult T cell leukemia\/lymphoma. Lancet Haematol, 2022. Under Review.","DOI":"10.1016\/S2352-3026(23)00087-X"},{"key":"2288_CR12","doi-asserted-by":"publisher","first-page":"881547","DOI":"10.3389\/fmed.2022.881547","volume":"9","author":"D Bradshaw","year":"2022","unstructured":"Bradshaw D, Taylor GP. HTLV-1 transmission and HIV Pre-exposure prophylaxis: a scoping review. Front Med. 2022;9:881547.","journal-title":"Front Med"},{"issue":"6","key":"2288_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/emboj\/20.6.1449","volume":"20","author":"SG Sarafianos","year":"2001","unstructured":"Sarafianos SG, et al. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. Embo j. 2001;20(6):1449\u201361.","journal-title":"Embo j"},{"key":"2288_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev.bb.25.060196.000553","volume":"25","author":"B Rost","year":"1996","unstructured":"Rost B, Sander C. Bridging the protein sequence-structure gap by structure predictions. Annu Rev Biophys Biomol Struct. 1996;25:113\u201336.","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"1","key":"2288_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cbdd.13388","volume":"93","author":"MT Muhammed","year":"2019","unstructured":"Muhammed MT, Aki-Yalcin E. Homology modeling in drug discovery: overview, current applications, and future perspectives. Chem Biol Drug Des. 2019;93(1):12\u201320.","journal-title":"Chem Biol Drug Des"},{"key":"2288_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.biopha.2018.10.139","volume":"109","author":"A Soltani","year":"2019","unstructured":"Soltani A, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother. 2019;109:770\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"7873","key":"2288_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"5","key":"2288_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1110\/ps.041253405","volume":"14","author":"B Wallner","year":"2005","unstructured":"Wallner B, Elofsson A. All are not equal: a benchmark of different homology modeling programs. Protein Sci. 2005;14(5):1315\u201327.","journal-title":"Protein Sci"},{"issue":"4","key":"2288_CR19","doi-asserted-by":"publisher","first-page":"e1007449","DOI":"10.1371\/journal.pcbi.1007449","volume":"16","author":"Y Haddad","year":"2020","unstructured":"Haddad Y, Adam V, Heger Z. Ten quick tips for homology modeling of high-resolution protein 3D structures. PLoS Comput Biol. 2020;16(4):e1007449.","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"2288_CR20","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1021\/acsomega.8b00721","volume":"3","author":"DM Nikolaev","year":"2018","unstructured":"Nikolaev DM, et al. A comparative study of modern homology modeling algorithms for rhodopsin structure prediction. ACS Omega. 2018;3(7):7555\u201366.","journal-title":"ACS Omega"},{"issue":"6","key":"2288_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","volume":"10","author":"LA Kelley","year":"2015","unstructured":"Kelley LA, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10(6):845\u201358.","journal-title":"Nat Protoc"},{"key":"2288_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev.biophys.29.1.291","volume":"29","author":"MA Mart\u00ed-Renom","year":"2000","unstructured":"Mart\u00ed-Renom MA, et al. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000;29:291\u2013325.","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"W1","key":"2288_CR23","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296-w303.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2288_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, et al. Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11(5):905\u201319.","journal-title":"Nat Protoc"},{"issue":"1","key":"2288_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","volume":"147","author":"E De Clercq","year":"2006","unstructured":"De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006;147(1):1\u201311.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2288_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/00002030-199908200-00006","volume":"13","author":"M Witvrouw","year":"1999","unstructured":"Witvrouw M, et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999;13(12):1477\u201383.","journal-title":"AIDS"},{"issue":"10","key":"2288_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0145-2126(90)90172-6","volume":"14","author":"T Isono","year":"1990","unstructured":"Isono T, Ogawa K, Seto A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk Res. 1990;14(10):841\u20137.","journal-title":"Leuk Res"},{"key":"2288_CR28","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell JS, Hunt SK, Chappell KJ, Integrated molecular and immunological features of HTLV-1 infection and disease progression to adult T cell leukemia\/lymphoma. Lancet Haematol 2023.","DOI":"10.1016\/S2352-3026(23)00087-X"},{"issue":"4","key":"2288_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/322785","volume":"184","author":"JG Garc\u00eda-Lerma","year":"2001","unstructured":"Garc\u00eda-Lerma JG, Nidtha S, Heneine W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J Infect Dis. 2001;184(4):507\u201310.","journal-title":"J Infect Dis"},{"issue":"5","key":"2288_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/v3050469","volume":"3","author":"B Macchi","year":"2011","unstructured":"Macchi B, et al. Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors. Viruses. 2011;3(5):469\u201383.","journal-title":"Viruses"},{"issue":"1","key":"2288_CR31","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1038\/s41467-021-25284-1","volume":"12","author":"MS Barski","year":"2021","unstructured":"Barski MS, et al. Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures. Nat Commun. 2021;12(1):4996.","journal-title":"Nat Commun"},{"issue":"16","key":"2288_CR32","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.1074\/jbc.273.16.9785","volume":"273","author":"HS Misra","year":"1998","unstructured":"Misra HS, Pandey PK, Pandey VN. An enzymatically active chimeric HIV-1 reverse transcriptase (RT) with the RNase-H domain of murine leukemia virus RT exists as a monomer. J Biol Chem. 1998;273(16):9785\u20139.","journal-title":"J Biol Chem"},{"issue":"7","key":"2288_CR33","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1074\/jbc.M507660200","volume":"281","author":"MS Mitchell","year":"2006","unstructured":"Mitchell MS, et al. Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase. J Biol Chem. 2006;281(7):3964\u201371.","journal-title":"J Biol Chem"},{"issue":"3","key":"2288_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1021\/acs.chemrev.6b00440","volume":"117","author":"P Li","year":"2017","unstructured":"Li P, Merz KM. Metal ion modeling using classical mechanics. Chem Rev. 2017;117(3):1564\u2013686.","journal-title":"Chem Rev"},{"issue":"1","key":"2288_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","volume":"91","author":"HJC Berendsen","year":"1995","unstructured":"Berendsen HJC, van der Spoel D, van Drunen R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun. 1995;91(1):43\u201356.","journal-title":"Comput Phys Commun"},{"issue":"23","key":"2288_CR36","doi-asserted-by":"publisher","first-page":"234505","DOI":"10.1063\/1.2121687","volume":"123","author":"JLF Abascal","year":"2005","unstructured":"Abascal JLF, Vega C. A general purpose model for the condensed phases of water: TIP4P\/2005. J Chem Phys. 2005;123(23):234505.","journal-title":"J Chem Phys"},{"issue":"16","key":"2288_CR37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785\u201391.","journal-title":"J Comput Chem"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02288-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02288-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02288-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T11:12:54Z","timestamp":1704885174000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02288-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2288"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02288-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.25.542289","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was sought or required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}